GlassScriptPhysician profile
Gregory Scott Forrester
NPI 1184284473
$7,386.22
in general payments reported to CMS, 2019-2025
24 companies · $1,789 in 2025
The $1,789 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $927 · 2022: $1,104 · 2023: $1,640 · 2024: $1,927 · 2025: $1,789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,246 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,245.71 |
| Education | $109.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,484.02 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,478.49 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $608.14 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Vanda Pharmaceuticals INC. | $486.60 | 2022-2025 | Fanapt, Hetlioz |
| Idorsia Pharmaceuticals US INC | $444.37 | 2022-2025 | Quviviq, Quviviq |
| Alkermes, INC. | $383.44 | 2021-2025 | Lybalvi, Aristada |
| Neurocrine Biosciences, INC. | $351.26 | 2021-2024 | Ingrezza |
| Lundbeck LLC | $276.33 | 2022-2025 | Rexulti |
| Corium, LLC | $268.24 | 2023-2024 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $264.01 | 2021-2023 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $197.68 | 2024-2025 | Austedo Xr, Austedo Xr |
| Eisai INC. | $196.78 | 2021-2022 | |
| Indivior INC. | $162.73 | 2022-2023 | Perseris |
| Takeda Pharmaceuticals U.S.A., INC. | $130.38 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $125.00 | 2024 | Auvelity |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $121.20 | 2025 | Veozah |
| Biogen, INC. | $114.44 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $104.19 | 2025 | Cobenfy |
| Merck Sharp & Dohme LLC | $90.11 | 2021-2023 | Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.93 | 2023 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $17.59 | 2021 | |
| Exact Sciences Corporation | $15.14 | 2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $14.24 | 2022 | |
| Lilly USA, LLC | $12.91 | 2023 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Forrester listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.